Catalog No.
DVV03111
Expression system
Mammalian Cells
Species reactivity
Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env
Concentration
2.1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04578
Form
Liquid
Storage buffer
100 mM Pro-Ac, 20 mM Arg, pH 5.0
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
10E8#
Note
For research use only. Not suitable for clinical or therapeutic use.
Enhancement of Neutralization Responses through Sequential Immunization of Stable Env Trimers Based on Consensus Sequences from Select Time Points by Mimicking Natural Infection., PMID:37628824
Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells., PMID:37681958
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation., PMID:37696048
Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load., PMID:37744365
Soluble CD4 and low molecular weight CD4-mimetic compounds sensitize cells to be killed by anti-HIV cytotoxic immunoconjugates., PMID:37772823
Liposome-based peptide vaccines to elicit immune responses against the membrane active domains of the HIV-1 Env glycoprotein., PMID:37793559
Higher HIV-1 Env gp120-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity Is Associated with Lower Levels of Defective HIV-1 Provirus., PMID:37896832
Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility., PMID:37940661
Molecular dynamics simulations show how antibodies may rescue HIV-1 mutants incapable of infecting host cells., PMID:38111161
Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9., PMID:38311724
Clinical, epidemiological, and drug resistance insights into HIV-positive patients in Meizhou, China., PMID:38314093
A two-step mechanism for the binding of the HIV-1 MPER epitope by the 10E8 antibody onto biosensor-supported lipid bilayers., PMID:38339834
Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1., PMID:38370662
Competitive assembly resolves the stoichiometry of essential proteins in infectious HIV-1 virions., PMID:38559103
A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals., PMID:38562833
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS., PMID:38587079
HIV-1 envelope facilitates the development of protease inhibitor resistance through acquiring mutations associated with viral entry and immune escape., PMID:38699474
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans., PMID:38761800
Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates., PMID:38768344
Vaccination induces broadly neutralizing antibody precursors to HIV gp41., PMID:38816615
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in presence of CD4-mimetics., PMID:38883797
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity., PMID:38895270
Applying Flow Virometry to Study the HIV Envelope Glycoprotein and Differences Across HIV Model Systems., PMID:38932227
Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs., PMID:38979012
Natural Variation in HIV-1 Entry Kinetics Map to Specific Residues and Reveal an Interdependence Between Attachment and Fusion., PMID:38979136
Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation., PMID:39028623
The Performance of the Current Algorithm of HIV Diagnosis., PMID:39086412
Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity., PMID:39115361
mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies., PMID:39119336
Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation., PMID:39176008
Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques., PMID:39213340
Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics., PMID:39230306
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity., PMID:39248460
Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate., PMID:39283123
Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening., PMID:39314380
A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity., PMID:39336102
Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody., PMID:39446590
Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells., PMID:39466835
Stoichiometry of HIV-1 Envelope Glycoprotein Protomers with Changes That Stabilize or Destabilize the Pretriggered Conformation., PMID:39484577
Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation., PMID:39508605
Vaccine-elicited and naturally elicited antibodies differ in their recognition of the HIV-1 fusion peptide., PMID:39611147
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies., PMID:39675002
Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles., PMID:39721354
Isolation and structure of broad SIV-neutralizing antibodies reveal a proximal helical MPER epitope recognized by a rhesus multi-donor class., PMID:39792559
The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs., PMID:40089599
Ab initio prediction of specific phospholipid complexes and membrane association of HIV-1 MPER antibodies by multi-scale simulations., PMID:40192122
Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes., PMID:40239787
Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening., PMID:40382314
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning., PMID:40383778
HIV-1 envelopes from virions that persist in plasma on antiretroviral therapy show reduced susceptibility to autologous immunoglobulins and variable sensitivity to broadly neutralizing monoclonal antibodies., PMID:40502069
For research use only. Not for human or drug use.
